Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients With Urea Cycle...(Buphenyl.com or by contacting Ucyclyd P...),Health
Navigation Links
| HOME >> MEDICINE >> TECHNOLOGY |
Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients With Urea Cycle Disorders
Date:7/22/2008
Buphenyl.com or by contacting Ucyclyd Pharma, Inc.
'/>"/>
| SOURCE Hyperion Therapeutics, Inc. Copyright©2008 PR Newswire. All rights reserved |
Related medicine technology :
1. Hyperion Therapeutics Announces Enrollment of First Patient in Phase 1/2 Clinical Trial of GT4P in Patients With Urea Cycle Disorders
2. William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
3. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
6. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
7. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
8. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
9. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
10. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
11. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
Post Your Comments:
Breaking Medicine Technology:China-Biotics, Inc. to Hold 2009 Annual Meeting of Stockholders on March 5, 2010 2China-Biotics, Inc. to Hold 2009 Annual Meeting of Stockholders on March 5, 2010 3Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 2Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 3Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 4Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 5Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 6Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 7Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 8Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 9Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 10Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 11Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 12Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 13Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 14Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 15Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 16Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 17Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 18News brief 3A Estrogen receptor alpha breast cancer patients and tamoxifen response 62159 1New stress related gene modulates high blood pressure in mice and men 62157 1New stress related gene modulates high blood pressure in mice and men 62157 2Type 1 Diabetes May Have a New Foe 62155 1Type 1 Diabetes May Have a New Foe 62155 2Type 1 Diabetes May Have a New Foe 62155 3
Other Medicine Technology:A Drug With Efficacy Superior to That of Xenical at Inducing Weight Loss Would Earn a 40 Percent Patient Share in the Obesity Drug Market 2ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohn's Disease 2ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohn's Disease 3ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohn's Disease 4ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohn's Disease 5ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohn's Disease 6
Breaking Medicine News(10 mins):Health News:Minnesota Vikings Team With Memorial Blood Centers Again for Annual Blood Drive 2Health News:Entertainment Celebrities Support Red Cross Holiday Giving Campaign 2Health News:Entertainment Celebrities Support Red Cross Holiday Giving Campaign 3Health News:State $200 Million Behind in Payments to Agencies Providing Care to Thousands of Older Illinoisans 2Health News:New approach to emissions makes climate and air quality models more accurate, major study finds 2Health News:New approach to emissions makes climate and air quality models more accurate, major study finds 3Health News:Entest BioMedical Enters into LOI with Advanced Light Devices to Develop Laser Platform for Stem Cell / Laser COPD Treatment 2Health News:Entest BioMedical Enters into LOI with Advanced Light Devices to Develop Laser Platform for Stem Cell / Laser COPD Treatment 3
[0] Minnesota Vikings Team With Memorial Blood Centers Again for Annual Blood Drive[0] Entertainment Celebrities Support Red Cross Holiday Giving Campaign[0] State $200 Million Behind in Payments to Agencies Providing Care to Thousands of Older Illinoisans[0] New approach to emissions makes climate and air quality models more accurate, major study finds[0] Entest BioMedical Enters into LOI with Advanced Light Devices to Develop Laser Platform for Stem Cell / Laser COPD Treatment
Other Medicine News:Health News:Duane Reade Goes Pink to Support 2008 Komen New York City Race for the Cure(R) 2Health News:Duane Reade Goes Pink to Support 2008 Komen New York City Race for the Cure(R) 3Health News:Duane Reade Goes Pink to Support 2008 Komen New York City Race for the Cure(R) 4Health News:Both Parties Need Planks to Restore Scientific Integrity at the CDC 2Health News:Bialke Named Executive Director of Minnesota Nurses Association 2Health News:Study examines use of opioids 2Health News:NARSAD Introduces 'Healthy Minds Across America,' an International Event Recognizing the Toll of Mental Illness, on Sunday, Sept. 14 2Health News:NARSAD Introduces 'Healthy Minds Across America,' an International Event Recognizing the Toll of Mental Illness, on Sunday, Sept. 14 3Health News:Catholic Health Association Responds to Census Figures on the Uninsured: Important Not to Be Misled By Declining Uninsured - These Are Not Today's Numbers 2
Duane Reade Goes Pink to Support 2008 Komen New York City Race for the Cure(R)Both Parties Need Planks to Restore Scientific Integrity at the CDCBialke Named Executive Director of Minnesota Nurses AssociationStudy examines use of opioidsNARSAD Introduces 'Healthy Minds Across America,' an International Event Recognizing the Toll of Mental Illness, on Sunday, Sept. 14Catholic Health Association Responds to Census Figures on the Uninsured: Important Not to Be Misled By Declining Uninsured - These Are Not Today's Numbers
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |